Annexuzlimab
Based on 1 Customer Validation
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.67%
- Peso molecular:146.56 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Annexin A1/ANXA1
In Vitro
Annexuzlimab (MDX-124) (2.5-10 μM; 72 h) significantly reduces proliferation in a dose-dependent manner in ANXA1-expressing human cancer cell lines, with 10 μM causing >50% viability reduction in some breast and ovarian cell lines, but has no effect on non-ANXA1-expressing lung cancer cell lines[1].
Annexuzlimab (10-25 μM; 24 h) induces a dose-dependent G1 phase cell cycle arrest, with 25 μM causing the most pronounced effects (33.5% G1 increase in MDA-MB-231, 21.2% in A549, 10.8% in BxPC-3), and does not induce apoptosis[1].
Annexuzlimab (5 μM; 72 h) does not induce apoptosis in MCF-7 breast or Caco-2 colorectal cancer cells[1].
Annexuzlimab incubation of osteosarcoma cell lines significantly inhibits cell growth through dose-dependent cell cycle arrest and also significantly reduces the migration ability of osteosarcoma cell line[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, HCC1806, MDA-MB-231, MCF-7/TAMR7, BxPC-3, MIA PaCa-2, PANC-1, A2780, A2780cis, A2780ADR, Caco-2, HCT116, SW480, NCI-H69/CPR, A549, COR-L23, COR-L23.5010
-
Concentration:2.5-10 μM
-
Incubation Time:72 h
-
Result:Caused a significant dose-dependent reduction in cellular proliferation in all ANXA1-expressing breast, pancreatic, ovarian, colorectal, and some lung cancer cell lines compared to IgG1 isotype control; At 10 μM, MCF-7, HCC1806, and MDA-MB-231 had >50% viability reduction, MCF-7/TAMR7 had 21% reduction, BxPC-3 had 40% reduction, MIA PaCa-2 had 20% reduction, PANC-1 had 34% reduction, A2780 had 31% reduction, A2780cis had 48% reduction, A2780ADR had 72% reduction, Caco-2, HCT116, and SW480 had significant reduction, NCI-H69/CPR had 36% reduction, A549 had 37% reduction; Showed no anti-proliferative activity in non-ANXA1-expressing COR-L23 and COR-L23.5010 lung cancer cells.
-
Cell Line:BxPC-3, MIA PaCa-2, MDA-MB-231, A549
-
Concentration:10 μM, 25 μM
-
Incubation Time:24 h
-
Result:Induced a dose-dependent G1 phase cell cycle arrest compared to untreated control cells; At 25 mM, MDA-MB-231 had a 33.5% increase in G1 phase and 29.1% decrease in S phase, A549 had a 21.2% increase in G1 phase and 18.3% decrease in S phase, BxPC-3 had a 10.8% increase in G1 phase and 10.4% decrease in S phase; Did not induce apoptosis (no sub G0/G1 peak observed).
-
Cell Line:MCF-7, Caco-2
-
Concentration:5 μM
-
Incubation Time:72 h
-
Result:Showed no significant difference in the percentage of early or late apoptotic/necrotic cells compared to untreated control cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 9 weeks old, orthotopic inoculation with 4T1-luc murine triple-negative breast cancer cells)[1]
-
Dosage:1 mg/kg
-
Administration:i.v.; two doses on day 1 and day 8
-
Result:Significantly inhibited tumour growth versus vehicle control, achieving 23% tumour growth inhibition by day 15. Observed no noticeable change in body weight throughout the study.
Gene ID
Accession
P04083
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Peso molecular 146.56 kDa
-
Color Colorless to light yellow
-
Synonyms
MDX-124
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Annexuzlimab Related Classifications
HY-P991864 Related Classifications
Powered by Bioz